Authorization to sell the MolecuLight i:X fluorescence imaging device across Canada has been granted to MolecuLight Inc., representing a major clinical advancement for diagnosing and treating wound infections. The MolecuLight i:X is an innovative, handheld fluorescence imaging device, the prototype for which was previously featured by Medgadget. The Health Canada-approved device will provide clinicians with a reliable way to assess bacterial burden in chronic wounds in real-time, without the need for contrast agents or patient contact.
More than 180 patients have participated in clinical trials testing the efficacy of the device, with positive results. Specifically, the MolecuLight i:X “can improve sample quality, healing rates, screen for high levels of bacteria and detect wound subsurface heavy bacterial load as well as subclinical local infection in patients,” according to the company. Moreover, the device is easily integrated into the acute care workflow of hospitals.
The device’s approval marks a historical moment in wound care, since clinicians now have a simple, rapid, reliable means of gathering real-time, objective information about the bacterial status of wounds. Improved diagnosis and assessment at the bedside facilitates timelier and more accurate antimicrobial treatment plans, which improves patient quality of life and health economics.
Comments
